Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Edmond de Rothschild Private Equity

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 17
Average round size
info
The average size of a deal this fund participated in
$44M
Portfolio companies 15
Rounds per year 0.24
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.12
Exits 8
Key employees 6
Stages of investment
Private Equity

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Biopharma
  • Health Care
  • Medical
Summary

In 1953 was created Edmond de Rothschild Private Equity, which is appeared as VC. The leading representative office of defined VC is situated in the Paris. The company was established in Europe in France.

We also calculated 6 valuable employees in our database.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Edmond de Rothschild Private Equity, startups are often financed by Index Ventures, MP Healthcare Venture Management, Andera Partners. The meaningful sponsors for the fund in investment in the same round are Andera Partners, Index Ventures, Forbion Capital Partners. In the next rounds fund is usually obtained by Nicholas Benedict, Forbion Capital Partners, EMBL Ventures.

Considering the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2013. The fund is constantly included in less than 2 investment rounds annually. Comparing to the other companies, this Edmond de Rothschild Private Equity performs on 54 percentage points more the average number of lead investments. The top amount of exits for fund were in 2014.

Among the various public portfolio startups of the fund, we may underline Genkyotex, Covagen, Allecra Therapeutics For fund there is no match between the location of its establishment and the land of its numerous investments - Switzerland. We can highlight the next thriving fund investment areas, such as Children, Biotechnology. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Edmond de Rothschild Private Equity:
Typical Co-investors
Edmond de Rothschild Private Equity is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Edmond de Rothschild Private Equity:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from France
Funds with similar focus located in France:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Clean Energy Trust Chicago, Illinois, United States
Cloquet Capital Partners Connecticut, New York, United States
Decima Ventures New York, New York, United States
FEBE Ventures Central Region, Singapore, Singapore
Kuka Group China, Hangzhou, Zhejiang
MobilityFund Germany, Hamburg
Resolve Growth Partners Baltimore, Maryland, United States
Shanghai Ruizhe China, Shanghai
Toro Ventures Mexico, Nuevo León, Nuevo Leon
ZoomInfo Massachusetts, United States, Waltham

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Swiss Summit Capital

Financial Services
$25M05 Apr 2019 London, England, United Kingdom

Avalyn Pharma

Biopharma
Biotechnology
Medical
Pharmaceutical
$62M01 Jan 2017 Seattle, Washington, United States

Allecra Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$25M15 Jun 2016 Baden-Württemberg

Covagen

Biopharma
Biotechnology
Therapeutics
$64M09 Dec 2013 Zurich, Switzerland

OncoEthix

Biotechnology
Health Care
Medical
$19M07 Aug 2013 Lausanne, Vaud, Switzerland

Allecra Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$17M18 Apr 2013 Baden-Württemberg

GlycoVaxyn

Biotechnology
Manufacturing
Pharmaceutical
$20M05 Mar 2009 Zurich, Switzerland

PanGenetics

Pharmaceutical
$27M05 Mar 2008 Utrecht, Utrecht, Netherlands

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Edmond de Rothschild Private Equity?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 17
Average round size 44M
Rounds per year 0.24
Peak activity year 2013
Lead investments 2
Follow on index 0.12
Exits 8
Group Appearance index 0.82

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Swiss Summit Capital

Financial Services
$25M05 Apr 2019 London, England, United Kingdom

Avalyn Pharma

Biopharma
Biotechnology
Medical
Pharmaceutical
$62M01 Jan 2017 Seattle, Washington, United States

Allecra Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$25M15 Jun 2016 Baden-Württemberg

Covagen

Biopharma
Biotechnology
Therapeutics
$64M09 Dec 2013 Zurich, Switzerland

OncoEthix

Biotechnology
Health Care
Medical
$19M07 Aug 2013 Lausanne, Vaud, Switzerland

Allecra Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$17M18 Apr 2013 Baden-Württemberg

GlycoVaxyn

Biotechnology
Manufacturing
Pharmaceutical
$20M05 Mar 2009 Zurich, Switzerland

PanGenetics

Pharmaceutical
$27M05 Mar 2008 Utrecht, Utrecht, Netherlands
Crunchbase icon

Content report

The following text will be sent to our editors: